Skip to main content
Erschienen in: International Journal of Colorectal Disease 2/2014

01.02.2014 | Original Article

ypN0 nodal status after neoadjuvant chemoradiotherapy for rectal carcinoma is not associated with adverse prognosis as compared with pN0 after primary surgery

verfasst von: Katharina Erlenbach-Wünsch, Sabine Semrau, Rainer Fietkau, Klaus Weber, Werner Hohenberger, Tilman Rau, Arndt Hartmann, Susanne Merkel, Abbas Agaimy

Erschienen in: International Journal of Colorectal Disease | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Neoadjuvant chemoradiotherapy (nCRT) has been established as standard treatment for locally advanced rectal cancer (cT3/4 or cN+ cM0, distance from circumferential resection margin ≤1 mm) to enhance local disease control and minimize the rate of locoregional recurrence. As a consequence of downstaging, a significant proportion of patients show non-viable tumor deposits within regional lymph nodes that qualify as ypN0 according to the current TNM classification irrespective of the actual pre-treatment status. Accordingly, the prognostic relevance of ypN0 status as compared with true pN0 without preceding nCRT is not known.

Patients and methods

We retrospectively analyzed 132 patients who underwent standard total mesorectal excision (TME) surgery after nCRT for rectal carcinoma and were classified as ypN0, and compared their prognoses with those of 341 patients with pN0 without nCRT.

Results

Re-evaluation of regional lymph nodes after nCRT showed no evidence of previous metastasis in 91 cases (ypN0(−)), sure but non-viable metastasis in 14 patients (ypN0(+)), and unsure status in 27 patients (ypN0(X)). The local recurrence rate, distant metastases, and disease-free, observed, and cancer-related survival were similar in all subgroups (p = 0.447, 0.695, 0.759, 0.655, and 0.354, respectively).

Conclusion

Our results showed a similar outcome in patients with ypN0 and in the control group with pN0 regarding local recurrence rate, distant metastases, and disease-free, observed, and cancer-related survival. Validation of these results is necessary to clarify the questions regarding postoperative adjuvant chemotherapy for patients with ypN0(+).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef
2.
Zurück zum Zitat Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19–23PubMedCrossRef Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19–23PubMedCrossRef
3.
Zurück zum Zitat Caricato M, Ausania F, De Dominicis E, Vincenzi B, Rabitti C, Tonini G, Cellini F, Coppola R (2007) Tumor regression in mesorectal lymph nodes after neoadjuvant chemoradiation for rectal cancer. Eur J Surg Oncol 33:724–728PubMedCrossRef Caricato M, Ausania F, De Dominicis E, Vincenzi B, Rabitti C, Tonini G, Cellini F, Coppola R (2007) Tumor regression in mesorectal lymph nodes after neoadjuvant chemoradiation for rectal cancer. Eur J Surg Oncol 33:724–728PubMedCrossRef
4.
Zurück zum Zitat Perez RO, Habr-Gama A, Arazawa STN, Rawet V, Siqueira SAC, Kiss DR, Gama-Rodrigues JJ (2005) Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. Int J Colorectal Dis 20:434–439PubMedCrossRef Perez RO, Habr-Gama A, Arazawa STN, Rawet V, Siqueira SAC, Kiss DR, Gama-Rodrigues JJ (2005) Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. Int J Colorectal Dis 20:434–439PubMedCrossRef
5.
Zurück zum Zitat Newman LA, Pernick NL, Adsay V, Carolin KA, Philip PI, Sipierski S, Bouwman DL, Kosir MA, White M, Visscher DW (2003) Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 10:734–739PubMedCrossRef Newman LA, Pernick NL, Adsay V, Carolin KA, Philip PI, Sipierski S, Bouwman DL, Kosir MA, White M, Visscher DW (2003) Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 10:734–739PubMedCrossRef
6.
Zurück zum Zitat Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, Park JW, Oh JH, Lim SB, Choi HS, Jeong SY (2010) Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiat Oncol Biol Phys 77:1158–1165PubMedCrossRef Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, Park JW, Oh JH, Lim SB, Choi HS, Jeong SY (2010) Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiat Oncol Biol Phys 77:1158–1165PubMedCrossRef
7.
Zurück zum Zitat Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696PubMedCrossRef Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696PubMedCrossRef
8.
Zurück zum Zitat Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. EORTC Radiotherapy Group Trial 22921. N Engl J Med 355:1114–1123PubMedCrossRef Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. EORTC Radiotherapy Group Trial 22921. N Engl J Med 355:1114–1123PubMedCrossRef
9.
Zurück zum Zitat Fietkau R, Barten M, Klautke G, Klar E, Ludwig K, Thomas H, Brinckmann W, Friedrich A, Prall F, Hartung G, Küchenmeister U, Kundt G (2006) Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy for rectal cancer. Dis Colon Rectum 49:1284–1292PubMedCrossRef Fietkau R, Barten M, Klautke G, Klar E, Ludwig K, Thomas H, Brinckmann W, Friedrich A, Prall F, Hartung G, Küchenmeister U, Kundt G (2006) Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy for rectal cancer. Dis Colon Rectum 49:1284–1292PubMedCrossRef
10.
Zurück zum Zitat Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM (2009) Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biological predictor of outcome. Cancer 115:5432–5440PubMedCrossRef Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM (2009) Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biological predictor of outcome. Cancer 115:5432–5440PubMedCrossRef
11.
Zurück zum Zitat Sprenger T, Rothe H, Jung K, Christiansen H, Conradi LC, Ghadimi BM, Becker H, Liersch T (2010) Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol 8:27PubMedCentralPubMedCrossRef Sprenger T, Rothe H, Jung K, Christiansen H, Conradi LC, Ghadimi BM, Becker H, Liersch T (2010) Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol 8:27PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Rullier A, Laurent C, Capdepont M, Vendrely V, Belleannée G, Bioulac-Sage P, Rullier E (2008) Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status and impact on survival. Am J Surg Pathol 32:45–50PubMedCrossRef Rullier A, Laurent C, Capdepont M, Vendrely V, Belleannée G, Bioulac-Sage P, Rullier E (2008) Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status and impact on survival. Am J Surg Pathol 32:45–50PubMedCrossRef
13.
Zurück zum Zitat Lindebjerg J, Spindler KL, Ploen J, Jakobsen A (2009) The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy. Colorectal Dis 11:264–269PubMedCrossRef Lindebjerg J, Spindler KL, Ploen J, Jakobsen A (2009) The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy. Colorectal Dis 11:264–269PubMedCrossRef
14.
Zurück zum Zitat Berardi R, Mantello G, Scartozzi M, Del Prete S, Luppi G, Martinelli R, Fumagalli M, Grillo-Ruggieri F, Bearzi I, Mandolesi A, Marmorale C, Cascinu S (2009) Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome. Int J Radiat Oncol Biol Phys 75:1437–1443PubMedCrossRef Berardi R, Mantello G, Scartozzi M, Del Prete S, Luppi G, Martinelli R, Fumagalli M, Grillo-Ruggieri F, Bearzi I, Mandolesi A, Marmorale C, Cascinu S (2009) Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome. Int J Radiat Oncol Biol Phys 75:1437–1443PubMedCrossRef
15.
Zurück zum Zitat UICC (2009) Sobin LH, Gospodarowicz MK, Wittekind Ch, eds. TNM Classification of Malignant Tumors, 7th edn. Wiley-Blackwell, Oxford, UK UICC (2009) Sobin LH, Gospodarowicz MK, Wittekind Ch, eds. TNM Classification of Malignant Tumors, 7th edn. Wiley-Blackwell, Oxford, UK
16.
Zurück zum Zitat Spreafico F, Gandola L, D'Angelo P, Terenziani M, Collini P, Bianchi M, Provenzi M, Indolfi P, Pession A, Nantron M, Di Cataldo A, Marchianò A, Catania S, Fossati Bellani F, Piva L, AIEOP Wilms Tumor Working Group (2012) Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Int J Radiat Oncol Biol Phys 82:348–354PubMedCrossRef Spreafico F, Gandola L, D'Angelo P, Terenziani M, Collini P, Bianchi M, Provenzi M, Indolfi P, Pession A, Nantron M, Di Cataldo A, Marchianò A, Catania S, Fossati Bellani F, Piva L, AIEOP Wilms Tumor Working Group (2012) Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Int J Radiat Oncol Biol Phys 82:348–354PubMedCrossRef
17.
Zurück zum Zitat Heald RJ, Husband EM, Ryall RDH (1982) The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 69:613–616PubMedCrossRef Heald RJ, Husband EM, Ryall RDH (1982) The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 69:613–616PubMedCrossRef
18.
Zurück zum Zitat Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, German Rectal Cancer Study Group (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13:679–687PubMedCrossRef Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, German Rectal Cancer Study Group (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13:679–687PubMedCrossRef
Metadaten
Titel
ypN0 nodal status after neoadjuvant chemoradiotherapy for rectal carcinoma is not associated with adverse prognosis as compared with pN0 after primary surgery
verfasst von
Katharina Erlenbach-Wünsch
Sabine Semrau
Rainer Fietkau
Klaus Weber
Werner Hohenberger
Tilman Rau
Arndt Hartmann
Susanne Merkel
Abbas Agaimy
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 2/2014
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-013-1790-x

Weitere Artikel der Ausgabe 2/2014

International Journal of Colorectal Disease 2/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.